In June, an independent FDA advisory committee overwhelmingly voted against approving the treatment. The committee raised concerns about the integrity of the trial data, particularly around safety and potential bias in efficacy results. The committee also noted the difficulty in determining how much of the treatment’s success was due to the accompanying talk therapy, which the FDA does not regulate.